14 hasil untuk "F. Lessi"
Menampilkan 1–14 · 1,16 detik · RSS
-
Artikel Jurnal
DP037 | PERIANAL DISEASE IN ACUTE LEUKEMIA PATIENTS: RISK FACTORS AND MANAGEMENT OF A RARE BUT FEARSOME COMPLICATION
Background: Perianal infections (fistulas, abscesses) in acute leukemia (AL) patients (pts) occur with an incidence of 7.3%. Because the poor clinical presentation in neutropenic pts, mortality rate is high. There is no universally accepted treatment strategy. Aim: Evaluate risk factors and…
-
Artikel Jurnal Teks lengkap
Seed-dispersing bird assemblages in riparian environments of a partially urbanized river basin, Southeastern Brazil
Abstract Birds play a key role in ecosystem dynamics, including urban and rural areas, bringing environmental quality improvements and ecological stability. Species contribute directly to natural regeneration of vegetation and succession processes, by offering ecosystem services as seed dispersal…
-
Artikel Jurnal Teks lengkap
ECOLOGICAL-ECONOMIC ZONING OF THE CITY OF ALTINÓPOLIS – SP, BRAZIL
ABSTRACT: Since colonial times, Brazilian land use has been made under an extractivist model at the expense of deforestation, increasing soil and vegetation depletion, stream siltation, as well as loss of biodiversity. An ecological-economic zoning (EEZ) has been taken as feasible alternative to…
-
Artikel Jurnal
Molecular profiling of microinvasive breast cancer microenvironment progression
Abstract Background Tumors develop by progression through a series of stages. Every cell of the tumor microenvironment is constantly changing in the flow of the cancer progression. It has become clear in recent years that stroma is essential for tumor maintenance and growth. Here, we aimed to give…
-
Artikel Jurnal
DP025 | INDUCTION THERAPY IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: INNOVATIONS IN THE ERA OF HYPOMETHYLATING AGENTS AND VENETOCLAX COMBINATION THERAPY
Background Prior to the approval of hypomethylating agents (HMAs) in combination with venetoclax (Ven) as first-line therapy for newly diagnosed Acute Myeloid Leukemia (AML) in 2017, intensive chemotherapy (ICT) was the only viable option for achieving remission in fit elderly patients. However…
-
Artikel Jurnal
P066 | FACTORS INFLUENCING MOLECULAR RELAPSE IN FAVORABLE-RISK, INTENSIVELY-TREATED, NPM1-MUTATED ACUTE MYELOID LEUKEMIA
As per 2021 ELN guidelines, for NPM1-mutated AML patients only the end-of-treatment (EOT) MRD is considered a clinically relevant biomarker, with thresholds of qPCR NPM1mut/ABL1% >2% (hereafter defined as NPM1%) and logarithmic reduction relative to diagnosis 2% or LogR2% or LogR2.1% was observed…
-
Artikel Jurnal
P057 | HYPERLEUKOCYTOSIS AND EXTRAMEDULLARY INVOLVEMENT IN ACUTE MYELOID LEUKEMIA: THE ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Background Newly diagnosed cases of Acute Myeloid Leukemia (AML) are stratified according to the 2022 European LeukemiaNet (ELN) recommendations based on their cytogenetic and molecular profiles. However, the literature suggests that hyperleukocytosis (HL) and extramedullary involvement (EI) may…
-
Artikel Jurnal
DP035 | THE ROLE OF ANTIFUNGAL PROPHYLAXIS IN ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING CONSOLIDATION CHEMOTHERAPY. A SEIFEM PROSPECTIVE, MULTICENTER STUDY
Background. The SEIFEM2016 study showed significant mortality from invasive fungal infection (IFI) in elderly patients (pts) with acute myeloid leukemia (AML) undergoing consolidation course (CC). To address the role of antifungal prophylaxis (AF) in this population, we conducted a multicenter…
-
Artikel Jurnal
DP040 | NOVEL GENETIC VARIANTS AND OLIGOGENIC MECHANISMS IN IDIOPATHIC ERYTHROCYTOSIS: A TARGETED NEXT-GENERATION SEQUENCING APPROACH
Idiopathic erythrocytosis (IE) includes a heterogeneous group of disorders defined by increased red cell mass without secondary causes or known clonal mutations. While advances in molecular diagnostics have uncovered variants in genes related to oxygen sensing, erythropoietin signaling, iron…
-
Artikel Jurnal
C086 | CHARACTERIZATION OF TP53 MUTATED ACUTE MYELOID LEUKEMIA TREATED WITH CPX-351: SUBANALYSIS FROM A LARGE REAL WORLD ITALIAN STUDY
CPX-351 has been approved for the treatment of patients (pts) with Acute Myeloid Leukemia (AML) with myelodysplasia related changes (AML-MRC) or therapy-related (t-AML). TP53 mutations (TP53m) affect at least 20-35% of such AML subtypes and confer dismal prognosis. We previously conducted a…